OBI Announces Final Arbitral Award in Contract Dispute with Biosion
Clinical Development and Global Strategy Continue as Planned with Related Programs Unaffected

Taipei, Taiwan, April 1, 2026 — OBI Pharma (4174.TWO) today announced that it has received the final award issued under the Delaware Rapid Arbitration Act in the United States in relation to its dispute with Biosion. The award determined that Biosion shall bear a portion of the Expenses incurred by OBI in the development of the TROP2 ADC.